Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Minocycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.71 |
| ▸ | MAPT | P10636 | 6/20 | 0.71 |
| ▸ | USP2 | O75604 | 5/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.69 |
| ▸ | GRK6 | P43250 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | ALB | P02768 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Minocycline SCHEMBL1446032 | 1.00 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL19063414 | 1.00 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL29946502 | 1.00 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL2539 | 1.00 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL6550323 | 1.00 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL2865953 | 1.00 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL2537 | 1.00 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL4810001 | 1.00 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL3969889 | 0.99 | TDP1 (0.70) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL5175145 | 0.99 | TDP1 (0.70) | TDP1KDM4EMAPTUSP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230304064-A1 | AUTOMATED, DIGITAL DISPENSING PLATFORM FOR MICRODILUTION ANTIMICROBIAL SUSCEPTIBILITY TESTING | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-09-28 | — | — | US | disclosed |
| EP-3873432-A1 | TETRACYCLINE COMPLEXES WITH SUSTAINED ACTIVITY | FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. (DE) | 2021-09-08 | — | — | EP | disclosed |
| EP-3655104-A1 | AN OSTEOADSORPTIVE FLUOROGENIC SUBSTRATE OF CATHEPSIN K FOR IMAGING OSTEOCLAST ACTIVITY AND MIGRATION | The Regents of the University of California (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-3469095-A1 | AUTOMATED, DIGITAL DISPENSING PLATFORM FOR MICRODILUTION ANTIMICROBIAL SUSCEPTIBILITY TESTING | Beth Israel Deaconess Medical Center, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| WO-2019018238-A1 | AN OSTEOADSORPTIVE FLUOROGENIC SUBSTRATE OF CATHEPSIN K FOR IMAGING OSTEOCLAST ACTIVITY AND MIGRATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2017218202-A1 | AUTOMATED, DIGITAL DISPENSING PLATFORM FOR MICRODILUTION ANTIMICROBIAL SUSCEPTIBILITY TESTING | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| EP-3240800-A1 | CLOSTRIDIUM DIFFICILE TARGETING MOIETIES AND CONSTRUCTS COMPRISING SAID MOIETIES | C3 JIAN, LLC (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3166959-A1 | TARGETING PEPTIDES THAT BIND S. MUTANS, CONSTRUCTS COMPRISING SUCH PEPTIDES AND USES THEREOF | C3 Jian, Inc. (US) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016109443-A1 | CLOSTRIDIUM DIFFICILE TARGETING MOIETIES AND CONSTRUCTS COMPRISING SAID MOIETIES | C3 JIAN, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| EP-3030084-A2 | ORGANOPHOSPHATES FOR TREATING AFFLICTIONS OF THE SKIN | Attillaps Holdings (US) | 2016-06-15 | — | — | EP | disclosed |
| US-7544373-B2 | Minocycline oral dosage forms for the treatment of acne | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-7541347-B2 | Minocycline oral dosage forms for the treatment of acne | MEDICIS PHARMACEUTICAL COROPRATION (US) | 2009-06-02 | — | — | US | disclosed |
| US-20090041846-A1 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008121107-A1 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242641-A1 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080241197-A1 | MINOCYCLINE DOSAGE FORMS FOR THE TREATMENT OF ACNE | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080241235-A1 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080241241-A1 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080242642-A1 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080241236-A1 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2008-10-02 | — | — | US | disclosed |